Supplementary Figures 1-7 from A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer
Year: 2023
Type: supplementary-materials
Abstract: Figure S1 Assessment of the RNA loading in the LbL nanoparticles; Figure S2. MiR-34a, miR-34c, and KRAS are under-expressed in KP lung tumors than healthy lungs while CD44 is overexpressed in KP lung tumors; Figure S1 Assessment of the RNA loading in the LbL nanoparticles; Figure S3 Representative cross-section of ex vivo microCT images of lung tumors, indicated by the white nodes spread throughout the lung area; Figure S4: Physicochemical characterization of liposome/PLA/Cy5.5-labelled siRNA & RNA/PLA/HA LbL nanoparticles; Figure S5. (a) Survival rates of mice that were treated with 16 mg/kg cisplatin dosing. (b) Survival rates of mice that were treated with 8 mg/kg cisplatin dosing; Figure S6. H&E staining of kideny and liver sections of mice that received combinatory LbL nanoparticles with various cisplatin concentration; Figure S7. Serum chemistry confirmed the renal damages of the mice that received LbL nanoparticles with cisplatin dosing of 16 mg/kg and free cisplatin solution dosing of 8 mg/kg.
Authors: Li Gu, Zhou J. Deng, Sweta Roy, Paula T. Hammond
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361886674